Terumo (OTCMKTS:TRUMY) Issues Earnings Results, Misses Estimates By $0.06 EPS

Terumo (OTCMKTS:TRUMY) issued its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. Terumo had a return on equity of 10.44% and a net margin of 13.83%.

Terumo Stock Performance

TRUMY traded down $1.03 on Thursday, hitting $14.75. 22,099 shares of the company traded hands, compared to its average volume of 233,765. The company has a 50 day moving average of $14.83 and a 200-day moving average of $14.08. The company has a quick ratio of 1.37, a current ratio of 2.19 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $21.76 billion, a PE ratio of 20.77 and a beta of 0.82. Terumo has a 12-month low of $12.08 and a 12-month high of $16.81.

Analysts Set New Price Targets

A number of research firms have recently commented on TRUMY. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.